KalVista Pharmaceuticals, Inc.

NASDAQ:KALV

Biotechnology

Healthcare
$27.00 +0.00%

+$0.00 today

Market cap
$1.44B
Beta
-0.11
P/E (TTM)
-9.9
EPS (TTM)
-$2.74
52W Low $9.83High $27.00

Volume 4.26M

Average 3.47M

KALV Deferred Revenue

Payments received for goods or services the company will deliver within the next year.

KalVista Pharmaceuticals, Inc.NASDAQ: KALV

Deferred Revenue · Q4 FY2026 · quarter ended Dec 2025

Deferred revenue of $0 in Q4 FY2026

Q4 FY2026 deferred revenue was $0.

Context

  • Deferred revenue amounted to 0.0% of total assets at the end of Q4 FY2026.
  • Deferred revenue increased in 1 of the last 3 fiscal years.
  • FY2026 was the lowest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterDec 2025
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
Deferred Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Deferred Revenue history

USD · from the balance sheet

Latest · FY2026
0 USD
Year-over-year change
-100.0%

Deferred Revenue vs competitors

How KALV compares with its peers on the latest reported figures

  • KALV's Dec 2025 deferred revenue of $0 is the 6th highest of the 10 companies compared; the peer median is $360K.
  • Deferred revenue amounts to 0.0% of total assets for KALV, versus a peer median of 0.1%.
KALV Competitors Peer median
Deferred Revenue for KALV and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
GOSSGossamer Bio, Inc.Mar 2026$8.74M -51.0%—6.8%
OMEROmeros CorporationMar 2026$2.82M ——1.0%
BCYCBicycle Therapeutics plcMar 2026$2.8M -77.7%-47.5%0.4%
PRTAProthena Corporation plcMar 2026$1.63M -79.4%-38.5%0.5%
FDMT4D Molecular Therapeutics, Inc.Mar 2026$360K -58.4%-25.9%0.1%
KALVKalVista Pharmaceuticals, Inc.Dec 2025$0 ——0.0%
OLMAOlema Pharmaceuticals, Inc.Mar 2026$0 ——0.0%
RIGLRigel Pharmaceuticals, Inc.Mar 2026$0 -100.0%-53.5%0.0%
VSTMVerastem, Inc.Mar 2026$0 ——0.0%
ADCTADC Therapeutics S.A.Mar 2026$0 ——0.0%
Peer median (excluding KALV) $360K-77.7%-43.0%0.1%

Competitors are the stored peer set for KALV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2022
Apr 2022
FY2023
Apr 2023
FY2024
Apr 2024
FY2025
Apr 2025
FY2026
Dec 2025
Cash & Equivalents30.73M56.24M31.79M98.64M229.34M
Short-term Investments135.47M93.14M178.61M89M70.87M
Net Receivables16.81M18.64M10.87M15.14M11.3M
Inventory00003.43M
Other Current Assets00019.21M0
Total Current Assets193.65M172.33M225.69M241.69M320.15M
Property, Plant & Equipment (Net)10.04M10.77M9.15M1.99M12.86M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets193K106K567K7.09M2.37M
Total Non-current Assets10.23M10.88M9.71M9.08M15.23M
Total Assets203.88M183.2M235.4M250.77M335.38M
Account Payables3.64M4.82M9.11M4.88M8.27M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00011M0
Other Current Liabilities4.17M4.21M6.69M036.8M
Total Current Liabilities11.58M15.03M22.81M45.17M57.36M
Long-term Debt0000139.23M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)000105.88M11.71M
Other Non-current Liabilities0000119.06M
Total Non-current Liabilities7.21M7.15M6.02M110.21M280.73M
Total Liabilities18.79M22.18M28.82M155.38M338.09M
Common Stock25K34K42K50K51K
Retained Earnings(250.18M)(343.08M)(469.73M)(653.17M)(762.69M)
Accumulated OCI(3.86M)(3.06M)(3.49M)(5.21M)(7.13M)
Other Stockholders Equity00000
Minority Interest00000
Total Equity185.09M161.03M206.58M95.39M(2.71M)
Total Debt8.19M8.23M7.32M6.31M151.58M
Net Debt(22.54M)(48.01M)(24.47M)(92.34M)(77.77M)

KalVista Pharmaceuticals, Inc.

NASDAQ:KALV

Intrinsic Alpha fair value

Locked

Current Price

$27.00

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.